|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RGS9 |
Gene summary for RGS9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RGS9 | Gene ID | 8787 |
| Gene name | regulator of G protein signaling 9 | |
| Gene Alias | PERRS | |
| Cytomap | 17q24.1 | |
| Gene Type | protein-coding | GO ID | GO:0001975 | UniProtAcc | O75916 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8787 | RGS9 | S015 | Human | Liver | HCC | 5.35e-05 | 1.70e-01 | 0.2375 |
| 8787 | RGS9 | S027 | Human | Liver | HCC | 1.09e-12 | 9.09e-01 | 0.2446 |
| 8787 | RGS9 | S028 | Human | Liver | HCC | 1.80e-12 | 4.44e-01 | 0.2503 |
| 8787 | RGS9 | S029 | Human | Liver | HCC | 1.62e-17 | 7.03e-01 | 0.2581 |
| 8787 | RGS9 | HTA12-15-2 | Human | Pancreas | PDAC | 5.41e-05 | 5.24e-01 | 0.2315 |
| 8787 | RGS9 | HTA12-26-1 | Human | Pancreas | PDAC | 1.32e-09 | 5.11e-01 | 0.3728 |
| 8787 | RGS9 | HTA12-29-1 | Human | Pancreas | PDAC | 2.28e-29 | 6.81e-01 | 0.3722 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007121421 | Liver | HCC | cellular response to abiotic stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:010400421 | Liver | HCC | cellular response to environmental stimulus | 183/7958 | 331/18723 | 1.59e-06 | 2.26e-05 | 183 |
| GO:00714782 | Liver | HCC | cellular response to radiation | 104/7958 | 186/18723 | 1.48e-04 | 1.19e-03 | 104 |
| GO:00323552 | Liver | HCC | response to estradiol | 81/7958 | 141/18723 | 2.39e-04 | 1.79e-03 | 81 |
| GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RGS9 | SNV | Missense_Mutation | rs570957320 | c.667N>A | p.Val223Ile | p.V223I | O75916 | protein_coding | tolerated(0.13) | benign(0.052) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| RGS9 | SNV | Missense_Mutation | rs190284951 | c.1706N>A | p.Arg569Gln | p.R569Q | O75916 | protein_coding | tolerated_low_confidence(0.74) | benign(0) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| RGS9 | SNV | Missense_Mutation | novel | c.1056G>C | p.Glu352Asp | p.E352D | O75916 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS9 | SNV | Missense_Mutation | novel | c.981N>T | p.Glu327Asp | p.E327D | O75916 | protein_coding | deleterious(0) | possibly_damaging(0.904) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RGS9 | SNV | Missense_Mutation | c.1735G>A | p.Ala579Thr | p.A579T | O75916 | protein_coding | tolerated_low_confidence(0.16) | benign(0.091) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
| RGS9 | SNV | Missense_Mutation | c.1543N>T | p.Arg515Trp | p.R515W | O75916 | protein_coding | deleterious_low_confidence(0.05) | benign(0.424) | TCGA-E2-A14Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| RGS9 | insertion | Nonsense_Mutation | novel | c.362_363insACATGATGCTCCTTGCTCATTCTTGGAGTGACAAAGTGT | p.Tyr121delinsTer | p.Y121delins* | O75916 | protein_coding | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| RGS9 | SNV | Missense_Mutation | c.1236C>G | p.Ile412Met | p.I412M | O75916 | protein_coding | tolerated(0.39) | possibly_damaging(0.865) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| RGS9 | SNV | Missense_Mutation | c.1543N>T | p.Arg515Trp | p.R515W | O75916 | protein_coding | deleterious_low_confidence(0.05) | benign(0.424) | TCGA-3L-AA1B-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RGS9 | SNV | Missense_Mutation | rs756410417 | c.1729C>T | p.Arg577Cys | p.R577C | O75916 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.996) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |